The Pattern

Over decades of managing a complex multi-system autoimmune disease, a consistent and unusual pattern has emerged in how my system responds to medications. The pattern has two distinct components that sometimes appear together and sometimes independently.

First, my system frequently responds to drugs through secondary or off-label mechanisms rather than primary ones, and responds faster and more durably than clinical literature would predict for either mechanism. Drugs that are supposed to take weeks work overnight. Drugs that are supposed to provide hours of relief provide days. Drugs with modest secondary anti-inflammatory properties produce primary anti-inflammatory effects.

Second, medications I tolerate well on an as-needed basis consistently become intolerable when taken daily, producing reactions that make continued use unsafe or impractical. This pattern has repeated across drug classes and mechanisms with enough consistency that it now functions as a clinical rule: daily pharmaceutical exposure is not compatible with my system.

The practical consequence of both phenomena is that I currently take no daily pharmaceutical medications. Everything is PRN. Understanding this pattern is essential to my safety. I self-manage dosing frequency as a necessary practice — PRN dosing allows me to assess my response and choose to dose again when the effect drops. I genuinely want a provider who can engage with this openly and be a real partner in managing it.

The Two Core Phenomena

Amplified and Unexpected Mechanism Response

My system responds to certain medications with effects that exceed what the primary mechanism would predict, often through secondary pharmacological pathways. The response is faster in onset, greater in magnitude, and longer in duration than standard clinical expectations.

Two biologics — tocilizumab and abatacept — produced immediate neurological adverse reactions after very short exposure and were discontinued. Two others produced no effect of any kind. The split maps onto a mechanistic distinction: drugs with meaningful reach into central and autonomic signaling territory produced immediate amplified reactions; drugs confined to the peripheral inflammatory compartment produced nothing.

Pregabalin at therapeutic doses produced sudden loss of postural tone — clinically consistent with negative myoclonus — that resolved within days of discontinuation.

The antibiotic allergy history shows progressive sensitization: penicillin allergy at age six, sulfa allergy within a year, subsequent allergic reactions to every antibiotic class attempted. Erythromycin is the only antibiotic tolerated without reaction.

Single observation, May 21 2026: High-dose IV nutrient infusion (glutathione 2g, vitamin C 15g, magnesium, B12, NAC, B-complex) produced dramatic functional and cognitive restoration within the infusion window following a morning of inability to walk due to inflammatory pain and significant cognitive/mood impairment. Effects persisted the following day without additional dosing. Pattern is consistent with systemic reset dynamic rather than symptomatic suppression. May suggest RA symptom burden is primarily driven by systemic inflammatory load rather than joint-specific pathology, which would also explain zero response to local/joint-targeted interventions such as topical diclofenac. Insufficient data for conclusions — noting for pattern tracking.

Sensitization Through Continuous Exposure

Medications tolerated on a PRN basis for extended periods have consistently produced serious reactions when daily dosing was introduced — either by a prescriber’s protocol change or by increased frequency of use. Once this occurs, the drug is effectively foreclosed because the severity of the reaction makes rechallenge an unacceptable risk.

The sensitization has a threshold character — PRN use below a certain exposure frequency is tolerated indefinitely, and crossing that threshold produces a reaction whose consequences may be permanent. The threshold varies by drug but the pattern is consistent.

Progressive Loss of Regulatory Tools

The consequences of sensitization in this system extend beyond adverse reaction risk. Each permanently foreclosed medication also removes a functional regulatory tool from an already limited management landscape. Several of the lost agents were not merely suppressing symptoms; they were partially stabilizing inflammatory momentum through distinct mechanisms that current alternatives do not fully replicate.

Hydroxychloroquine represented a major loss. Intermittent PRN use produced rapid anti-inflammatory benefit disproportionate to its expected primary mechanism, likely through amplified response to secondary innate immune signaling effects. Daily exposure ultimately produced catastrophic neurological consequences and permanent vestibular impairment, foreclosing further use entirely. The system lost not only a therapeutic option but one of the few pharmaceutical interventions capable of producing meaningful regulatory interruption without immediate destabilization during PRN use.

Ibuprofen was a significant tool for many years and remains one. Three angioedema episodes occurred in early 2026, the third requiring emergency intervention; ibuprofen was initially considered a likely trigger and NSAIDs were flagged as a class concern. Dr. Afrasiabi (allergist/immunologist) was not convinced ibuprofen was the cause: both episodes involved a 15-hour latency inconsistent with a direct mechanism, and ibuprofen has been taken multiple times since — and continues to be taken — without reaction. Hereditary angioedema and acquired C1 inhibitor deficiency have since been formally excluded by lab workup, as has autoimmune urticaria; specialists favor a non-bradykinin explanation, and no further workup is currently planned. Ibuprofen remains an active part of the PRN toolkit.

This pattern changes the practical meaning of pharmaceutical risk. In a typical clinical picture, loss of one medication usually leaves multiple comparable alternatives. In this system, each lost intervention narrows a highly individualized and already constrained regulatory toolkit. The remaining tolerated interventions become increasingly load-bearing as the management landscape contracts.

Future prescribing decisions carry asymmetric consequences. A failed or destabilizing trial may not simply produce a temporary adverse event. It may permanently eliminate another regulatory mechanism from a system with diminishing redundancy and limited remaining therapeutic flexibility.

The Deeper Mechanism — Compensatory Equilibrium and System Architecture

A more fundamental explanation underlies both phenomena. A system that has been chronically dysregulated for decades does not simply have elevated inflammatory markers — it reorganizes itself around those elevations. The thrombocytosis, the elevated IgA, the persistent RF, the entire laboratory pattern — these are not purely pathological. They represent a compensatory architecture the system has constructed under duress, with multiple components partially ameliorating each other in ways that are largely unmapped.

High-specificity pharmaceutical intervention targeting a single component of that architecture does not just reduce one signal — it destabilizes a finely balanced compensatory equilibrium. The amplification reactions and permanent damage that have followed certain pharmaceutical exposures may reflect this destabilization as much as receptor sensitivity alone. The system may respond with speed and intensity not because a single receptor is hypersensitive, but because a load-bearing point within a compensatory adaptive architecture has been disrupted.

This may help explain why natural and physiological interventions — helminthic therapy, betaine HCl, nutritional supplementation — have been tolerated without these reactions. They work with the compensatory architecture rather than targeting specific components of it. The distinction that matters is not natural versus synthetic, but whether an intervention engages the system through high-specificity molecular perturbation of a single target or through diffuse physiological support of existing pathways.

The Reset Dynamic

Across multiple drugs and mechanisms, a specific inflammatory dynamic has emerged that goes beyond simple symptom relief. Inflammation in this system does not sit at a continuous level — it builds momentum. Certain interventions interrupt that momentum and produce durable resets: the inflammatory trajectory restarts from a lower baseline and takes considerable time to rebuild. The reset effect persists well beyond the drug’s active pharmacological window.

Prednisone produces the most powerful resets — a hard system interruption from which the inflammatory trajectory restarts and remains suppressed for an extended period before gradually rebuilding. Ibuprofen, hydroxychloroquine, and tramadol each produced softer versions of the same dynamic — interrupting momentum and producing resets that outlasted their pharmacological half-lives by days to weeks.

None of these drugs are classified as anti-inflammatories in the primary sense. Their reset effect in this system is an expression of the upstream regulatory signal amplification pattern — each touches autonomic or immune regulatory pathways, and the system responds with primary anti-inflammatory effect disproportionate to the drug’s primary classification.

The Drug Examples

Tramadol — Unexpected Anti-Inflammatory Durability

Tramadol is a centrally acting analgesic combining opioid receptor activity with serotonin and norepinephrine reuptake inhibition. Its anti-inflammatory properties — cytokine suppression via the SNRI component — are real but considered secondary and modest in clinical literature.

In my system, a single 50mg dose taken during an acute foot flare severe enough to prompt evaluation for fracture produced dramatic functional improvement in ambulation that persisted for several days. The effect was substantially anti-inflammatory in character rather than purely analgesic — the improvement in ease of movement exceeded what pain masking alone would explain, and the duration far exceeded tramadol’s plasma half-life.

Tramadol was taken daily at 50mg for approximately a decade with stable efficacy and no sensitization reaction. The only adverse effect that eventually developed was headaches, which are frequency-dependent — daily use produced migraine-level headaches that are not acceptable. The headache mechanism is likely serotonergic rather than immunological. Daily use is not compatible with this system. Tramadol remains in the toolkit on a PRN basis.

The tramadol story has a specific interpretation worth noting. The threshold crossing after a decade of daily use may not represent pure sensitization in the pharmacological sense. It may instead reflect the system itself changing — ongoing neurological deterioration reaching a point where the serotonergic load that had been tolerable became intolerable. If so, the tramadol story is less about a drug crossing a threshold and more about a system changing underneath a stable drug exposure until it could no longer accommodate what it had previously tolerated without difficulty.

Hydroxychloroquine — Overnight Response to a Weeks-Long Drug

Hydroxychloroquine’s primary mechanism — interference with lysosomal pH and antigen presentation — is genuinely slow. Clinical literature describes onset of therapeutic effect in weeks to months. It is not considered an acute anti-inflammatory agent.

My system responded overnight. Taken on an as-needed basis, HCQ produced rapid and meaningful symptom relief clinically inconsistent with its primary mechanism. The likely explanation is a secondary effect on toll-like receptor signaling and innate immune activation, which operates on a faster timescale than the primary lysosomal mechanism.

HCQ was tolerated well on a PRN basis for an extended period. Daily HCQ was initiated mid-to-late December 2025, following several months of deliberate resistance to an October 2025 provider recommendation — the PRN tolerance and the known risks of daily dosing in this system made the decision one to approach with caution. Acute vestibular crisis developed within days to two weeks of daily dosing — presentation indistinguishable from major stroke, inability to stand, emergency services called. Self-discontinued upon recognizing the connection approximately December 30 or early January 2026. Allergy formally documented January 13, 2026. Residual vestibular and balance damage did not fully resolve.

HCQ is permanently foreclosed. Another reaction of this severity could be incapacitating. The risk is not acceptable under any circumstances.

Ibuprofen — PRN Tolerance, Angioedema Episodes, Current Status

Ibuprofen has been tolerated on a PRN basis for many years and remains part of the active toolkit, providing effective anti-inflammatory and analgesic coverage with a characteristic durable reset effect extending days past the pharmacological window.

Three angioedema episodes occurred in early 2026, the third requiring emergency intervention. Ibuprofen was initially considered the likely trigger. Specialist evaluation by Dr. Afrasiabi (allergist/immunologist, Prescott) found both documented episodes involved a 15-hour latency inconsistent with a direct NSAID-mediated mechanism, and ibuprofen has been taken multiple times since the episodes — and continues to be taken regularly — without reaction. Subsequent lab workup formally excluded hereditary angioedema and acquired C1 inhibitor deficiency, as well as autoimmune urticaria. Two specialists favor a non-bradykinin explanation for the angioedema; the tranexamic acid response and the IgE/specific-allergen disconnect remain the strongest evidence for a bradykinin-pathway contribution, but this is not being pursued further. Ibuprofen is not implicated as the trigger, and use is not restricted on that basis.

Current status: ibuprofen is used regularly as part of the active PRN toolkit.

Dose-response observation: the standard dose has been 2×400mg (800mg total). A trial of 3×400mg (1200mg total) was substantially more effective. However, the higher dose produced increased bruising. Dosing has returned to 2×400mg despite the reduced efficacy, given the bruising risk. This is a real dose-response relationship with a bleeding-risk tradeoff, not yet discussed with a physician.

The prior multi-function role of ibuprofen — COX pathway modulation, hepcidin reduction via inflammatory suppression, mast cell modulation through prostaglandin effects, incidental antiplatelet activity — remains relevant to understanding what it was doing in the system beyond simple analgesia.

Duloxetine — Amplified Reaction on Two Separate Trials

Duloxetine 30mg was trialed twice, approximately two weeks apart, alongside ibuprofen. Both trials produced the same reaction: weak, exhausted, fatigued, and uncomfortable in my own skin — diffuse and systemic, not localized to any single nameable symptom. The reaction was reproducible across both trials.

Duloxetine’s common side effect profile does include fatigue and general malaise in the broader patient population. My own assessment is that this reaction fits the amplified/unexpected mechanism response pattern documented elsewhere in this system, rather than representing an ordinary, population-typical side effect. Both trials were single or brief exposures, not daily continuous use, so this has not been tested against the sensitization-through-continuous-exposure pattern — but if daily dosing had been continued, I suspect it would have crossed into that pattern as well, based on how this system has behaved with other drugs.

Duloxetine has not been continued.

Methotrexate — Catastrophic Failure

Methotrexate was a catastrophic failure. The primary adverse effects at standard doses include nausea, fatigue, and liver toxicity with long-term use. Neuropsychiatric effects are not a primary feature.

My experience was continuous, uncontrollable crying for the entire duration of waking hours — an effect so foreign to my baseline that it was immediately recognizable as drug-induced — combined with severe peripheral neuropathy described as the sensation of large insects biting. These effects appeared rapidly and resolved within approximately two weeks of discontinuation. The peripheral neuropathy did not fully resolve and remains a long-term consequence.

The crying and emotional dysregulation likely reflect folate depletion affecting neurotransmitter synthesis — a secondary mechanism of methotrexate — operating with unusual severity in my system. The speed of onset and the magnitude of effect are consistent with the amplification pattern seen with other drugs, expressed here as catastrophic adverse effect rather than unexpected benefit.

The treating rheumatologist attributed clinical improvement during the MTX trial to the drug. That improvement was almost certainly due to concurrent 60mg daily prednisone rather than any MTX effect — the prednisone was doing the work while the MTX was producing neurological damage. MTX is permanently foreclosed regardless.

Dr. William E. Merrell, MD — a board-certified internist with over 50 years of experience at Yavapai Regional Medical Center and former Chief of Staff, a physician who had known me for years and had observed me supporting my husband through Gleason 9 prostate cancer treatment without breaking — was visibly astonished at my presentation and equally astonished at my complete recovery two weeks after discontinuation.

Biologics — The No-Effect / Rapid Reaction Split

Four biologics were tried. Two produced no effect and no adverse reaction. Two produced rapid neurological adverse effects and were discontinued after very short exposure.

Humira (adalimumab) — 18 months, no improvement, no adverse effects.

Simponi (golimumab) — 9-12 months, no improvement, no adverse effects.

Actemra (tocilizumab) — rapid numbness and burning in extremities. One infusion was completed. A second infusion was cancelled due to neurological reaction — the practice logged this as a missed appointment rather than a patient-initiated cancellation. The treating rheumatologist believed the patient was responding to the drug; the patient disagreed. Discontinued.

Orencia (abatacept) — a strange peripheral sensory phenomenon after one or possibly two infusions: nerve endings felt as though they extended from the skin surface, with a breeze playing along them. Not unpleasant in itself, but recognized as a neurological reaction and discontinued. The decision to stop was influenced by prior methotrexate neurological damage — without that history, the sensation alone might not have prompted discontinuation.

The pattern is striking. The two drugs that produced no effect also produced no reaction — as though my system simply did not engage with them. The two that produced rapid neurological reactions engaged immediately and intensely. Humira and Simponi are TNF inhibitors — they operate primarily in the peripheral inflammatory compartment. Actemra blocks the IL-6 receptor and Orencia modulates T-cell costimulation through CTLA-4 — both have meaningful reach into central and autonomic signaling territory. The split maps onto a distinction between drugs that stay in the peripheral theater and drugs that reach the CNS and autonomic nervous system. My system engaged with the second category immediately and disproportionately.

When my system responds to a drug, it responds amplified. When it does not respond, it does not respond at all. There is no middle ground.

Antibiotic Allergy Progression

Beginning in infancy, recurrent ear infections were treated with continuous courses of penicillin — estimated at approximately ten courses per year. Penicillin allergy developed at age six. The only available alternative at the time was sulfa, which produced allergy within a year. Ear infections resolved after discontinuation of all antibiotics at age seven.

Since that time, allergic reactions have developed to every antibiotic class attempted: Keflex producing hives, ciprofloxacin producing choking sensation and hives within hours of the first dose. The reactions have accelerated in onset with each new exposure.

This progression suggests a generalized immune sensitization to novel molecular structures rather than class-specific allergy. Each sensitization event appears to have lowered the threshold for the next one. The early and prolonged antibiotic exposure in infancy, now recognized as clinically significant for dysbiosis development, may also have established the immune amplification tendency that characterizes all subsequent drug responses.

Erythromycin remains the only antibiotic known to be tolerated without reaction.